Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Stockholders Equity of $6.09 billion for the year ending 2025.
- BIOMARIN PHARMACEUTICAL INC showed an increase of +7.6% in Stockholders Equity from 2024 to 2025.
- This data is from BIOMARIN PHARMACEUTICAL INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2012: $1.02 billion | Q1 2013: $1.25 billion | Q2 2013: $1.26 billion | Q3 2013: $1.28 billion | Q1 2014: $1.46 billion | Q2 2014: $1.46 billion | Q3 2014: $1.51 billion | Q1 2015: $2.43 billion | Q2 2015: $2.36 billion | Q3 2015: $2.29 billion | Q1 2016: $2.29 billion | Q2 2016: $1.92 billion | Q3 2016: $2.65 billion | Q1 2017: $2.77 billion | Q2 2017: $2.80 billion | Q3 2017: $2.81 billion | Q1 2018: $2.81 billion | Q2 2018: $2.89 billion | Q3 2018: $2.91 billion | Q1 2019: $2.94 billion | Q2 2019: $2.96 billion | Q3 2019: $3.07 billion | Q1 2020: $3.24 billion | Q2 2020: $3.24 billion | Q3 2020: $4.05 billion | Q1 2021: $4.16 billion | Q2 2021: $4.24 billion | Q3 2021: $4.26 billion | Q1 2022: $4.39 billion | Q2 2022: $4.50 billion | Q3 2022: $4.57 billion | Q1 2023: $4.66 billion | Q2 2023: $4.78 billion | Q3 2023: $4.90 billion | Q1 2024: $5.07 billion | Q2 2024: $5.29 billion | Q3 2024: $5.41 billion | Q1 2025: $5.79 billion | Q2 2025: $6.03 billion | Q3 2025: $6.06 billion.
- Over the full 14 years of available data (2012 to 2025), BIOMARIN PHARMACEUTICAL INC's Stockholders Equity has grown by 499.3%.
- Historical annual values: Fiscal year 2025: $6.09 billion | Fiscal year 2024: $5.66 billion | Fiscal year 2023: $4.95 billion | Fiscal year 2022: $4.60 billion | Fiscal year 2021: $4.27 billion | Fiscal year 2020: $4.10 billion | Fiscal year 2019: $3.12 billion | Fiscal year 2018: $2.97 billion | Fiscal year 2017: $2.81 billion | Fiscal year 2016: $2.77 billion | Fiscal year 2015: $2.40 billion | Fiscal year 2014: $1.53 billion | Fiscal year 2013: $1.34 billion | Fiscal year 2012: $1.02 billion.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: